12.299. Image Credit: Sino Biological Inc. Immobilized MMAE-ADC at 1 μg/mL (100 μL/well) can bind the Anti-MMAE Antibody, the EC₅₀ of Anti-MMAE is 50 -1000 ng/mL. The naked antibody (without ...

Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows insufficient efficacy.

Additionally, IPH4502 shows efficacy in models resistant to MMAE-ADC. These results support its potential for development beyond UC and in cancer patients treated with MMAE-based ADCs. Innate ...

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with ...

and Pfizer’s ADC technology that utilizes a protease-cleavable linker that covalently attaches the microtubule-disrupting agent monomethyl auristatin E (MMAE) to the antibody. Nonclinical data ...

FibroGen (FGEN) announced the peer-reviewed publication titled “A Phase 1, First-in-Human Study of FOR46, an Immune-Modulating Antibody-Drug ...

Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation -- -- Plan to present preclinical data for EO-1022 at AACR ...

Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat ...

"With EO-1022, we are combining the most advanced site-specific conjugation technology platform with the clinically validated MMAE payload, which is widely used across ADC programs but has yet to ...